For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
China's anti-trust crackdown on foreign pharmaceutical companies has left many foreign investors in the healthcare industry shocked. The Chinese government has had no qualms about openly stating that it prefers hospitals to purchase from domestic producers. That said, China's homegrown manufacturers of medical devices and medicine still lack the sophistication to produce many of the more advanced health care products the country needs. Amid rising living standards and an aging population, China's healthcare needs are set to rise sharply in the coming years.
In April 2015, China amended its Drug Administration Law, introducing two major changes.
The first is a simplification of the company set-up procedure for pharmaceutical companies. Prior to the amendment, investors that wanted to manufacture or distribute pharmaceuticals needed to have a Drug Manufacturing License or a Drug Distribution License before applying for a business license. Now, investors may apply for these after the company has been set up, significantly speeding up the incorporation process.
More importantly, the amendment removes the price controls that the Chinese government had in place for medicines. As of the year 2000, medicines that were listed on the government's Medical Insurance Catalog, and those medicines on which there was a monopoly, had their prices fixed or guided by the government. About 23 percent of the medicines on the Chinese market had government fixed or guided prices. The price of other medicines was left to market forces. While these price restrictions are now fully removed, companies still need to abide by China's anti-trust laws. Companies abusing their dominant market position are still punishable under Chinese law.
While recent moves have made it easier for foreign investors to introduce new medical products to the Chinese market, the Chinese government has at the same time placed restraints on advertising healthcare products. The final text of the revised Advertising Law was released by the National People's Congress, China main legislative body, in late April 2015. The law comes into force in September 2015.
The 2015 Advertising Law has special stipulations about advertising for medicine and medical devices. For one, advertising for anesthetics, psychotropic drugs, toxic and radioactive drugs for medical use is not allowed, nor is advertisement for drugs, treatment plans and medical devices to combat drug addiction. Advertising for prescription drugs other than those mentioned previously is only allowed in professional medical journals.
The content for medical advertisements is regulated as well. Any advertisement for drugs, medical treatment or medical devices may not contain the following:
According to this study, over the next five years the Anti-Peptic Ulcer Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Anti-Peptic Ulcer Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Peptic Ulcer Drugs market by product type, application, key manufacturers and key regions and countries.
This study considers the Anti-Peptic Ulcer Drugs value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
- Proton Pump Inhibitors (PPIs)
- Potassium-Competitive Acid Blockers (P-CAB)
- H2 Antagonists
- Ulcer Protective Drugs
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
- Gastric Ulcers
- Duodenal Ulcers
- Gastroesophageal Reflux Disease (GERD)
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- - United States
- - Canada
- - Mexico
- - Brazil
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- - Germany
- - France
- - UK
- - Italy
- - Russia
- - Spain
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
- Yangtze River Pharm
- Shandong Luoxin
- Huadong Medicine
- Changzhou Siyao
- Beijing Yuekang
- Guangdong Dahua
- Xian Janssen
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
- To study and analyze the global Anti-Peptic Ulcer Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
- To understand the structure of Anti-Peptic Ulcer Drugs market by identifying its various subsegments.
- Focuses on the key global Anti-Peptic Ulcer Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
- To analyze the Anti-Peptic Ulcer Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
- To project the consumption of Anti-Peptic Ulcer Drugs submarkets, with respect to key regions (along with their respective key countries).
- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
- To strategically profile the key players and comprehensively analyze their growth strategies.